131 related articles for article (PubMed ID: 17965004)
21. [The potential of monoclonal antibodies in cancer : established trastuzumab and cetuximab and promising targets IGF-1R and c-MET].
Bodmer A; Goetsch L; Favet L; Bailly C; Corvaia N; Dietrich PY
Med Sci (Paris); 2009 Dec; 25(12):1090-8. PubMed ID: 20035684
[TBL] [Abstract][Full Text] [Related]
22. [Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials].
Azria D; Larbouret C; Robert B; Culine S; Ychou M; Verrelle P; Dubois JB; Pèlegrin A
Bull Cancer; 2003 Nov; 90 Spec No():S202-12. PubMed ID: 14763141
[TBL] [Abstract][Full Text] [Related]
23. [EGF receptors in colorectal cancers].
Spano JP; Vignot S
Bull Cancer; 2007; 94(7 Suppl):F171-6. PubMed ID: 17964993
[TBL] [Abstract][Full Text] [Related]
24. [EGFR/HER1: a target life].
Viel E; Curtit E; Mansi L; Vignot S
Bull Cancer; 2012 Feb; 99(2):181-9. PubMed ID: 21684835
[TBL] [Abstract][Full Text] [Related]
25. [Targeting epidermal growth factor receptor in cancer of the breast].
Diéras V; Pierga JY; Vincent-Salomon A; Beuzeboc P; Pouillart P; de Cremoux P
Bull Cancer; 2003 Nov; 90 Spec No():S257-62. PubMed ID: 14763149
[TBL] [Abstract][Full Text] [Related]
26. HER-2-positive breast cancer: hope beyond trastuzumab.
Bartsch R; Wenzel C; Zielinski CC; Steger GG
BioDrugs; 2007; 21(2):69-77. PubMed ID: 17402790
[TBL] [Abstract][Full Text] [Related]
27. How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors.
Milik SN; Lasheen DS; Serya RAT; Abouzid KAM
Eur J Med Chem; 2017 Dec; 142():131-151. PubMed ID: 28754471
[TBL] [Abstract][Full Text] [Related]
28. Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2.
Mayordomo C; García-Recio S; Ametller E; Fernández-Nogueira P; Pastor-Arroyo EM; Vinyals L; Casas I; Gascón P; Almendro V
J Cell Physiol; 2012 Apr; 227(4):1358-66. PubMed ID: 21604273
[TBL] [Abstract][Full Text] [Related]
29. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment.
Press MF; Lenz HJ
Drugs; 2007; 67(14):2045-75. PubMed ID: 17883287
[TBL] [Abstract][Full Text] [Related]
30. Targeting the EGFR in neoplasia--more questions than answers.
Dicker AP; Rodeck U
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):899-902. PubMed ID: 14967449
[No Abstract] [Full Text] [Related]
31. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
32. [Development of antibody drugs targeting against HER2 for cancer therapy].
Tang Q; Ding Q; Lin L; Zhang ZZ; Dai Z; Zhan JB
Yao Xue Xue Bao; 2012 Oct; 47(10):1297-305. PubMed ID: 23289141
[TBL] [Abstract][Full Text] [Related]
33. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
34. Update on HER1-3 in advanced non-small-cell lung cancer.
Horn L; Lovly C
J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S369-71. PubMed ID: 23160321
[No Abstract] [Full Text] [Related]
35. [Targeted therapy: what does it mean? A physician point of view].
Spano JP
Bull Cancer; 2007; 94(7 Suppl):F111-4. PubMed ID: 17964988
[TBL] [Abstract][Full Text] [Related]
36. ErbB receptors and signaling pathways in cancer.
Hynes NE; MacDonald G
Curr Opin Cell Biol; 2009 Apr; 21(2):177-84. PubMed ID: 19208461
[TBL] [Abstract][Full Text] [Related]
37. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
38. Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ("Iressa") and trastuzumab ("Herceptin").
Fukutome M; Maebayashi K; Nasu S; Seki K; Mitsuhashi N
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):528-36. PubMed ID: 16965995
[TBL] [Abstract][Full Text] [Related]
39. Targeting the HER2 receptor in metastatic breast cancer.
Orphanos G; Kountourakis P
Hematol Oncol Stem Cell Ther; 2012; 5(3):127-37. PubMed ID: 23095788
[TBL] [Abstract][Full Text] [Related]
40. Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy.
Kim JW; Kim JH; Im SA; Lee KH; Kim JS; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1023-9. PubMed ID: 24036907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
